A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy

A lentiviral vector targeting a KRAS neoepitope for cancer immunotherapy

Abstract Mutated oncogenic Kirsten rat sarcoma virus (KRAS) antigen is expressed in a large variety of cancers, including pancreatic, colorectal, and pulmonary cancers. The oncogenic KRAS mutations cause malignancies and are usually ubiquitously expressed by all cells of a tumor. The KRAS amino acid...

Full description

Saved in:
Bibliographic Details
Main Authors: Anastasia Goloudina, Fabien Le Chevalier, Pierre Authié, Sylvain Ciret, Kirill Nemirov, Ingrid Fert, Fanny Moncoq, Benjamin Vesin, Amandine Noirat, Catherine Blanc, Yu Wei, Pierre Charneau, Laleh Majlessi
Format: Article
Language:English
Published: Nature Portfolio 2025-07-01
Series:Scientific Reports
Subjects:
Cancer immunotherapy
Inhibition of tumor growth
KRAS oncogenic mutations
KRASG12D
Lentiviral vectors
Online Access:https://doi.org/10.1038/s41598-025-05134-6
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Mutated oncogenic Kirsten rat sarcoma virus (KRAS) antigen is expressed in a large variety of cancers, including pancreatic, colorectal, and pulmonary cancers. The oncogenic KRAS mutations cause malignancies and are usually ubiquitously expressed by all cells of a tumor. The KRAS amino acid substitutions at the positions 12 or 13 are among the most frequent mutations in human cancers. Here, we developed immuno-oncotherapeutic non-integrative lentiviral vectors encoding a segment encompassing KRASG12D, either alone, or associated with antigen carriers. These carriers can improve the intracellular antigen routing to major histocompatibility complex presentation machineries or provide universal helper CD4+ epitopes. Immunotherapy with one of these vectors resulted in significant immune control of tumor growth in colorectal or pulmonary preclinical cancer models, in several murine genetic backgrounds. The antitumor effect was correlated with increased proportions of intra-tumoral hematopoietic cells and notably CD8+ T cells. Although this effect was partial, it was robust, reproducible and advantageously combinable with conventional chemotherapies and immunotherapies to improve antitumor protection. Therefore, this approach shows promise as an immuno-oncotherapy against KRAS-mediated malignant transformation.
ISSN:2045-2322

Similar Items